Please login to the form below

Not currently logged in
Email:
Password:

Former NICE chair Sir Michael Rawlins to lead MHRA

He will take up his new role at the UK's medicines and devices regulator in December

sir-michael-rawlins-mhraThe UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has named UK healthcare veteran Sir Michael Rawlins as its new chair.

Sir Michael will take up his new post on December 1, 2014 and replace Sir Gordon Duff, who earlier this year announced his intention to step down from the regulator to focus on his academic career.

Sir Gordon has been in the position for just under two years during which time he has overseen a period of major change for the agency, which is responsible for protecting and improving the health of people in the UK

The task will now fall to Sir Michael, who is no stranger to senior positions in UK healthcare having spent 14 years as chairman of the National Institute for Health and Care Excellence (NICE) from its formation in 1999 to his departure last year.

He is also an honorary professor at the London School of Hygiene and Tropical Medicine, University of London, and emeritus professor at the University of Newcastle upon Tyne.

More recently Sir Michael has served on the board of US-based biotech Intra-Cellular Therapeutics.

The appointment was welcomed by England's chief medical officer Prof Dame Sally Davies.

“I am delighted at Sir Michael Rawlins' appointment as agency chair,” she said. “He will bring a wealth of experience to the Board and will play a key role in the leadership of our national regulator who will continue to focus on excellence and innovation.”

4th November 2014

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics